Indication

DS Stage I Plasma Cell Myeloma

1 clinical trial

1 product

3 drugs

Clinical trial

A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)

Status: Active (not recruiting), Estimated PCD: 2020-02-01

Drug

Product

Drug

Drug